Monday 10th February 2014 |
Text too small? |
Shares of Pacific Edge, which have soared almost 200 percent in the past 12 months, extended their gains after a deal was signed allowing its bladder cancer test to be used District Health Boards.
The stock jumped 4.9 cents to $1.72 after the Health Innovation Hub, a government agency set up to allow technology innovations to be commercialised via the nation's four largest DHBs, signed a commercial agreement for the adoption of Pacific Edge's Cxbladder test. The four biggest DHBs are Auckland, Waitemata, Counties-Manukau and Canterbury, covering almost half the country's population.
"The decision of HIH to now assist the adoption of Cxbladder is a strong endorsement of its ability to deliver sound clinical outcomes for patients and significant savings in time and expense for DHBs," chief executive David Darling said in a statement.
Last year, Pacific Edge announced two agreements with US healthcare network providers, giving it access to sell its CXbladder test to 44 million Americans. It also announced the first commercial sale to US clinicians. It raised some $20 million via a rights offer to drive sales growth.
BusinessDesk.co.nz
No comments yet
Spark New Zealand appoints new director to the Spark Board
AFT to announce full year results on May 23 2024
CRP - Korella North Takes Another Two Steps Forward
May 3rd Morning Report
ASB workers to strike as bank proposes an effective pay cut
Rising tides, sinking stocks: study explores cost of climate change
May 2nd Morning Report
AGL - Change in Senior Management
Devon Funds Morning Note - 01 May 2024
Rick Christie to step-aside as a non-executive director